Geovax Labs Inc. (GOVX) – StreetInsider.com Reports
-
Geovax Labs (GOVX) Presents Data on GEO-CM04S1
-
Geovax Labs (GOVX) Achieves Milestone in Transition to Commercially Validated Manufacturing System
-
Geovax Labs Inc. (GOVX) Files $100M Mixed Shelf
-
GeoVax Labs, Inc. (GOVX) Reports FY Loss of $14.29
-
Geovax Labs Inc. (GOVX) Regains Nasdaq Compliance
-
Geovax Labs (GOVX) Announces New Patent Issuances and Allowances
-
Geovax Labs (GOVX) Reports Positive Interim Data From Phase 2 Trial of GEO-CM04S1
-
Geovax Labs Inc. (GOVX) Announces 1:15 Reverse Share Split
-
Geovax Labs (GOVX) Announces Issuance of Malaria Vaccine Patent
-
Geovax Labs Inc. (GOVX) Announces 21.13M Share Offering by Selling Stockholders
-
Geovax Labs Inc. (GOVX) Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
-
Geovax Labs Inc. (GOVX) announces update on key strategic initiatives
-
Geovax Labs Inc. (GOVX) Receives Notice of Allowance for HIV Vaccine Patent
-
Geovax (GOVX) Secures Multi-Product License for ProBioGen's AGE1.CR.pIX Suspension Cell Line
-
Geovax Labs (GOVX) Presents Next-Generation COVID-19 Vaccine Data
-
Geovax Labs Inc. (GOVX) Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients
-
Geovax (GOVX) Receives Notice of Allowance for Malaria Vaccine Patent
-
Geovax (GOVX) Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
-
GeoVax Labs, Inc. (GOVX) Misses Q2 EPS by 5c
-
Geovax Labs (GOVX) Announces Issuance of Ebola Vaccine Patent
-
Geovax Labs (GOVX) Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
-
Geovax Labs Inc. (GOVX) Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights
-
Geovax Labs Inc. (GOVX) Partners With ABL to Advance cGMP Production of Vaccine Candidates
-
Geovax Labs's (GOVX) Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients
-
Noble Capital Starts GeoVax Labs Inc. (GOVX) at Outperform, PT $6
-
Geovax Labs Inc. (GOVX) Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses
-
Geovax Labs (GOVX) Presents Data for GEO-MM01
-
GeoVax Labs, Inc. (GOVX) Misses Q4 EPS by 63c
-
Dawson James Starts GeoVax Labs Inc. (GOVX) at Buy, PT $4
-
Geovax (GOVX) and EmVenio Collaborate to Expand Phase 2 COVID-19 Booster Vaccine Trial
-
Geovax Labs Inc. (GOVX) Expands Gedeptin Clinical Research for Advanced Head and Neck Cancers
-
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.03%
-
Geovax Labs (GOVX) Receives Notice of Allowance for Zika Vaccine Patent
-
Geovax Labs Inc. (GOVX) Appoints Jayne Morgan, M.D., to its Board of Directors
-
CG Capital Starts GeoVax Labs Inc. (GOVX) at Outperform
-
GeoVax Labs Inc. (GOVX) PT Lowered to $3 at Maxim Group
-
GeoVax Labs, Inc. (GOVX) Tops Q3 EPS by 2c
-
UPDATE: H.C. Wainwright Starts GeoVax Labs Inc. (GOVX) at Buy
-
Geovax Labs Inc. (GOVX) Climbs 48%
-
Geovax Labs Inc. (GOVX) Climbs 50%
-
Geovax Labs Inc. (GOVX) Reports Publication of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization
-
Geovax Labs Inc. (GOVX) Climbs 27%
-
French Health Minister Francois Braun Says About 1700 People Have Been Infected With Monkey Pox In France - Reuters
-
Geovax Labs Inc. (GOVX) Extends Gain, Now Up 120%
-
Pre-Open Movers: Monkeypox Plays Jump on WHO Warning; Weber Falls on Weak Results
-
Geovax Labs Inc. (GOVX) Prices $20M Direct and PIPE Offerings at $1.65/sh
-
Geovax Labs Inc. (GOVX) Receives Notice of Allowance for Cancer Vaccine Patent in China
-
Geovax Labs Inc. (GOVX) Announces Issuance of Malaria Vaccine Patent
-
Geovax Labs Inc. (GOVX) Granted Cancer Vaccine Patent
-
Geovax Labs Inc. (GOVX) Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials
Back to GOVX Stock Lookup
